IGM Biosciences Nears Acquisition by Concentra Biosciences

IGM Biosciences has agreed to be acquired by Concentra Biosciences for $1.247 per share in cash plus a contingent value right (CVR), which offers shareholders potential additional payments based on surplus cash and proceeds from certain asset sales within a year after closing. The merger, unanimously approved by IGM's Board, requires a majority tender of shares and at least $82 million in cash availability, with a tender offer to begin by mid-July and deal closure expected in August 2025. Despite IGM's recent stock decline and financial challenges including significant cash burn and negative EBITDA, the deal has boosted investor confidence, causing a roughly 20% stock surge in premarket trading. IGM focuses on engineered IgM-based therapeutic antibodies, and the acquisition reflects ongoing consolidation trends in the biotech sector as companies seek to enhance innovation and streamline operations. Legal counsel for the deal includes Wilson Sonsini Goodrich & Rosati for IGM and Gibson, Dunn & Crutcher for Concentra. The transaction is subject to customary closing conditions and regulatory filings will follow the tender offer commencement.